Skip to main content

Epilepsy and cannabis in Alabama

The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Listed qualifying condition
✓ Yes
LEGAL
Physician-certified med…
POSSESSION
$65/yr
STATE FEE
7–30 d
TIMELINE
Listed qualifying condition. The state explicitly lists this condition under its medical cannabis program. A certifying physician can pursue state registration for a patient with this diagnosis under the program rules.

Alabama statute and program

The Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) is the operating authority for Alabama patient certification. The authoritative legal text is: Alabama Compassion Act (SB 46 of 2021).

What the evidence says about cannabis and Epilepsy

Epilepsy is a chronic neurological disorder defined by recurrent unprovoked seizures. The condition affects an estimated 3.4 million Americans. Most patients respond to anti-seizure medications, but approximately one-third develop treatment-resistant epilepsy that fails two or more first-line drugs.

For the full evidence base, including the NASEM tier, randomized trial summaries, and symptom-domain breakdown, read the mmjnow Epilepsy page.

How to qualify in Alabama

The Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) requires the following registration steps for a Epilepsy patient (or any qualifying diagnosis):

  1. See an Alabama-licensed certifying physician. Under the Darren Wesley "Ato" Hall Compassion Act (Alabama Act 2021-450), only physicians who have completed the four-hour Alabama Medical Cannabis Commission (AMCC) certification course and registered with the AMCC may certify patients. The physician evaluates the patient for one of the enumerated qualifying conditions (autism, cancer-related cachexia or chronic pain, Crohn’s, depression, epilepsy, HIV/AIDS, panic disorder, Parkinson’s, PTSD, sickle-cell, intractable pain, terminal illness, and others under §20-2A-3).
  2. Register through the AMCC patient portal. After certification, the patient creates an account in the AMCC patient registry using a current Alabama driver license or state ID. The physician’s certification is linked electronically to the patient’s record. Caregivers (required for minor patients) register separately and pass a state and federal background check.
  3. Pay the $65 state registration fee. The annual AMCC patient registration fee is $65 (caregiver registration is also $65). Once paid, the patient receives a digital medical cannabis card. The program does not yet have brick-and-mortar dispensaries open as of the program’s phased launch — operating dispensary licenses were issued in 2024 with retail expected to begin in 2025.
  4. Purchase from an AMCC-licensed dispensary. With the digital card and Alabama ID, patients may purchase Alabama-permitted forms (tablets, capsules, tinctures, gels, oils, gummies, lozenges, suppositories, topical patches, transdermal patches, nebulizers, and liquids or oils for use in an inhaler — no smokable flower, edibles intended to look like candy, or vaping products under §20-2A-3(15)). Adult-use cannabis remains illegal in Alabama.
State registration fee
$65
Physician visit (typical)
$200–$400
Certification to card
7–30 days
Out-of-state patients
Not eligible
Minors
Eligible with caregiver

For full Alabama registration steps, fees, and reciprocity rules, see the Alabama cannabis-laws page.

ICD-10 code

A certifying physician documenting Epilepsy for the Alabama medical cannabis program will typically record ICD-10 G40.909 or SNOMED-CT 84757009 in the patient's record. The state registry does not itself collect ICD-10 codes in most programs, but the physician's chart is the audit trail if the certification is later reviewed.

Frequently asked questions

Does Alabama list Epilepsy as a qualifying condition for medical cannabis?

Yes. Alabama explicitly lists Epilepsy as a qualifying condition under Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act). A patient with a documented Epilepsy diagnosis can pursue state-program certification with a physician registered in the state. The qualifying-condition list is set by state statute or regulation and may change. Inclusion on the list does not guarantee certification — a physician still has to evaluate the patient and decide that medical cannabis is appropriate for that specific case under Alabama rules.

How do I get a Alabama medical marijuana card for Epilepsy?

Step one is finding a physician licensed in Alabama who is registered with Alabama Medical Cannabis Program (Darren Wesley 'Ato' Hall Compassion Act) and willing to evaluate Epilepsy cases. Step two is collecting your records (diagnosis documentation, treatment history, and the ICD-10 code your physician will use) and bringing them to the certification visit. Step three is the physician's certification through the state registry, followed by the patient registration application, state fee, and waiting period before the card is issued. Alabama does not honor out-of-state cards, so the certification process has to originate inside the state. Verify the patient minimum age with the state program before applying. Confirm the current process with the state regulator before applying, because the rules change.

What does the evidence say about cannabis for Epilepsy?

For Epilepsy, evidence is described as strong (e.g. multiple randomized controlled trials or systematic reviews supporting effect). The mmjnow condition page for Epilepsy lays out the current evidence base, including the citations underlying that evidence tier — typically the National Academies of Sciences, Engineering, and Medicine consensus reports, federal agency guidance, and peer-reviewed reviews. Evidence quality is independent of state law: a state can list a condition for which evidence is limited, and a state can decline to list a condition for which evidence is strong. Patients deciding whether to pursue medical cannabis for Epilepsy should review the underlying evidence (linked on the condition page) and discuss expected benefit, dosing, and risk with a clinician familiar with both Epilepsy and cannabinoid pharmacology. Cannabis is not a substitute for evidence-based first-line treatments for Epilepsy; the evidence position above describes whether trial data supports its use, not whether it should replace standard care.

Sources

  1. Alabama Compassion Act (SB 46 of 2021)accessed May 16, 2026
  2. Alabama Medical Cannabis Commissionaccessed May 16, 2026
  3. Wikipedia: Cannabis in Alabamaaccessed May 16, 2026
  4. Ala. Code §13A-12-214: Unlawful possession of marijuana (penalty schedule)accessed May 17, 2026
  5. Alabama SB 46 (2021): Darren Wesley 'Ato' Hall Compassion Actaccessed May 17, 2026
  6. Alabama Department of Agriculture & Industries: Industrial Hemp Programaccessed May 17, 2026
  7. Alabama Legislature bill trackeraccessed May 17, 2026
  8. NASEM: The Health Effects of Cannabis and Cannabinoids (2017)accessed May 15, 2026

    “Conclusive or substantial evidence that oral cannabidiol is effective for the treatment of certain epilepsy syndromes.”

  9. FDA: Epidiolex (cannabidiol) prescribing informationaccessed May 15, 2026
  10. NIH NCCIH: Cannabis (Marijuana) and Cannabinoidsaccessed May 15, 2026